Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the organization to meet ...

London Organ-on-Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of Technology for Organ-on-Chip systems which connect human ...

CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of ...

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the opening of new laboratory facilities at ...

New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior CN Bio’s computational tools combine the ...

CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced ...

CN Bio, a provider of single- and multi-organ microphysiological systems, has raised a $21m investment in the first close of its Series B fundraising round. The investment will be used to accelerate ...

CN Bio has announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work ...

Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to ...

CN Bio Innovations (“CN Bio”), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has ...